Clinical Trials
Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials
AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the next weeks. The LAABs have been...
News
Gilead Sciences signs joint procurement agreement with the European Commission for Veklury (remdesivir)
Gilead Sciences and the EC signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir), the first antiviral drug proven to be effective for the treatment of COVID-19 in the European Union (EU)....
News
Regeneron’s REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients
Regeneron Pharmaceuticals, Inc. announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19....
News
BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1
BryoLogyx, Inc., announced that it has completed the synthesis of bryostatin-1 molecule, pursuant to FDA’s Good Manufacturing Practice (GMP) regulations. Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the...
Clinical Trials
Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials
At Johnson & Johnson, there is no greater priority than the safety and well being of the people we serve every day around the world. We are committed to providing transparent updates throughout the clinical development process of our...
News
New Zealand signs deal with Pfizer, BioNTech for Covid-19 vaccine
The New Zealand government signed a deal on Monday to buy 1.5 million COVID-19 vaccines from Pfizer Inc and Germany’s BioNTech, with delivery potentially as early as the first quarter of 2021.
The government did not disclose financial terms of...
News
Pistoia Alliance launches seed fund to drive biopharma and healthcare innovation
The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life science and healthcare R&D, launched its new Innovation Seed Fund to finance early stage concepts in biopharma and healthcare. It aims to fund...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.